BioSpace News Archive

Akebia Therapeutics®, Inc. announced it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023) taking place in San Diego, CA and virtually November 1-5, 2023.

ReGelTec, Inc., announced that the U.S. Food and Drug Administration has approved an IDE for the company’s pivotal study to support premarket approval of its HYDRAFIL® System.

Petros Pharmaceuticals, Inc., a company focused on expanding consumer access to medication through over the counter pathway, announces that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the LD Micro Main Event XVI.

MAIA Biotechnology, Inc., a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through September 2024.

NorthX Biologics AB is proud to announce the official inauguration of its state-of-the-art Innovation Hub at the Matfors facility.

Biovica International Biovica, active in cancer monitoring, announces that the Center for Medicare & Medicaid Services has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024.

Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology.

Turnstone Biologics Corp. announced four posters reporting preclinical data for Turnstone’s Selected TIL therapies will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.

Basilea Pharmaceutica Ltd, Allschwil announced that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine, one of the world’s leading peer-reviewed medical journals.